Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults

Journal of Allergy and Clinical Immunology

Volumn 131, Issue 5, 2013, Pages

  Creticos, Peter S ^a   Maloney, Jennifer ^b   Bernstein, David I ^c   Casale, Thomas ^d   Kaur, Amarjot ^b   Fisher, Robert ^e   Liu, Nancy ^b   Murphy, Kevin ^f   Nékám, Kristóf ^g   Nolte, Hendrik ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d CREIGHTON UNIVERSITY   (United States)

^e Allergy Research and Care   (United States)

^f BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^g Department of Internal Medicine   (Hungary)

Author keywords

allergic conjunctivitis; allergic rhinitis; allergic rhinoconjunctivitis; Allergy immunotherapy tablet; ragweed pollen; specific immunotherapy; sublingual immunotherapy

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOMODULATING AGENT; MK 3641; PLACEBO; SCH 39641; UNCLASSIFIED DRUG;

ADULT; AMBROSIA ARTEMISIIFOLIA; ANAPHYLACTIC SHOCK; APPARENT LIFE THREATENING EVENT; APPLICATION SITE REACTION; ARTICLE; ASTHMA; CLINICAL EVALUATION; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NORTH AMERICA; PRIORITY JOURNAL; RAGWEED; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SEASONAL VARIATION; SIDE EFFECT; SUBLINGUAL IMMUNOTHERAPY; SYMPTOM; TONGUE EDEMA; TREATMENT DURATION;

EID: 84876906083     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.03.019     Document Type: Article

References (39)

1. J.F. White, and D.I. Bernstein Key pollen allergens in North America Ann Allergy Asthma Immunol 91 2003 425 435
2. C. Oberhuber, Y. Ma, N. Wopfner, G. Gadermaier, A. Dedic, and B. Niggemann Prevalence of IgE-binding to Art v 1, Art v 4 and Amb a 1 in mugwort-allergic patients Int Arch Allergy Immunol 145 2008 94 101
3. R. Asero, N. Wopfner, P. Gruber, G. Gadermaier, and F. Ferreira Artemisia and ambrosia hypersensitivity: co-sensitization or co-recognition? Clin Exp Allergy 36 2006 658 665
4. G. Gadermaier, N. Wopfner, M. Wallner, M. Egger, A. Didierlaurent, and G. Regl Array-based profiling of ragweed and mugwort pollen allergens Allergy 63 2008 1543 1549
5. S.J. Arbes Jr., P.J. Gergen, L. Elliott, and D.C. Zeldin Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey J Allergy Clin Immunol 116 2005 377 383
6. L. Ziska, K. Knowlton, C. Rogers, D. Dalan, N. Tierney, and M.A. Elder Recent warming by latitude associated with increased length of ragweed pollen season in central North America Proc Natl Acad Sci U S A 108 2011 4248 4251
7. G.J. Burbach, L.M. Heinzerling, C. Röhnelt, K.C. Bergmann, H. Behrendt, and T. Zuberbier Ragweed sensitization in Europe - GA(2)LEN study suggests increasing prevalence Allergy 64 2009 664 665
8. L. Cox, H. Nelson, R. Lockey, C. Calabria, T. Chacko, and I. Finegold Allergen immunotherapy: a practice parameter third update J Allergy Clin Immunol 127 1 Suppl 2011 S1 S55
9. L.M. Lichtenstein, P.S. Norman, and W.L. Winkenwerder A single year of immunotherapy for ragweed hay fever. Immunologic and clinical studies Ann Intern Med 75 1971 663 671
10. L.M. Lichtenstein, P.S. Norman, W.L. Winkenwerder, and A.G. Osler In vitro studies of human ragweed allergy: changes in cellular and humoral activity associated with specific desensitization J Clin Invest 45 1966 1126 1136
11. S.R. Durham, W. Emminger, A. Kapp, J.G. de Monchy, S. Rak, and G.K. Scadding SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial J Allergy Clin Immunol 129 2012 717 725
12. N.M. Hsu, and W.R. Reisacher A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy Int Forum Allergy Rhinol 2 2012 280 284
13. T.G. Epstein, G.M. Liss, K. Murphy-Berendts, and D.I. Bernstein Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy: year 2 Ann Allergy Asthma Immunol 107 2011 426 431
14. D.I. Bernstein, M. Wanner, L. Borish, and G.M. Liss Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001 J Allergy Clin Immunol 113 2004 1129 1136
15. A. Bufe, P. Eberle, E. Franke-Beckmann, J. Funck, M. Kimmig, and L. Klimek Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy J Allergy Clin Immunol 123 2009 167 173.e7
16. U. Wahn, A. Tabar, P. Kuna, S. Halken, A. Montagut, and O. de Beaumont Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis J Allergy Clin Immunol 123 2009 160 166.e3
17. A. Didier, M. Worm, F. Horak, G. Sussman, O. de Beaumont, and M. Le Gall Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis J Allergy Clin Immunol 128 2011 559 566
18. M. Blaiss, J. Maloney, H. Nolte, S. Gawchik, R. Yao, and D.P. Skoner Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents J Allergy Clin Immunol 127 2011 64 71
19. H.S. Nelson, H. Nolte, P. Creticos, J. Maloney, J. Wu, and D.I. Bernstein Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults J Allergy Clin Immunol 127 2011 72 80
20. D. Skoner, D. Gentile, R. Bush, M.B. Fasano, A. McLaughlin, and R.E. Esch Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen J Allergy Clin Immunol 125 2010 660 666
21. C. André, M. Perrin-Fayolle, M. Grosclaude, P. Couturier, D. Basset, and J. Cornillon A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship Int Arch Allergy Immunol 131 2003 111 118
22. T. Bowen, J. Greenbaum, Y. Charbonneau, J. Hébert, R. Filderman, and G. Sussman Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis Ann Allergy Asthma Immunol 93 2004 425 430
23. R.E. Esch, R.K. Bush, D. Peden, and R.F. Lockey Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results Ann Allergy Asthma Immunol 100 2008 475 481
24. A.S. Nayak, G.J. Atiee, E. Dige, J. Maloney, and H. Nolte Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis Allergy Asthma Proc 33 2012 404 410
25. T.B. Casale, G.W. Canonica, J. Bousquet, L. Cox, R. Lockey, and H.S. Nelson Recommendations for appropriate sublingual immunotherapy clinical trials J Allergy Clin Immunol 124 2009 665 670
26. G.W. Canonica, J. Bousquet, T. Casale, R.F. Lockey, C.E. Baena-Cagnani, and R. Pawankar Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009 Allergy 64 Suppl 91 2009 1 59
27. European Medicines Agency Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases 2009 European Medicines Agency London
28. R. Dahl, A. Kapp, G. Colombo, J.G. de Monchy, S. Rak, and W. Emminger Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years J Allergy Clin Immunol 121 2008 512 518
29. J. Bousquet, N. Khaltaev, A.A. Cruz, J. Denburg, W.J. Fokkens, and A. Togias Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Allergy 63 Suppl 86 2008 8 160
30. P.S. Creticos, T.E. Van Metre, M.R. Mardiney, G.L. Rosenberg, P.S. Norman, and N.F. Adkinson Jr. Dose response of IgE and IgG antibodies during ragweed immunotherapy J Allergy Clin Immunol 73 1984 94 104
31. G.J. Gleich, E.M. Zimmermann, L.L. Henderson, and J.W. Yunginger Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study J Allergy Clin Immunol 70 1982 261 271
32. J. Bousquet, H.J. Schünemann, P.J. Bousquet, C. Bachert, G.W. Canonica, and T.B. Casale How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2)LEN statement Allergy 66 2011 765 774
33. F. Kette, and W. Smith Sublingual immunotherapy: allergen specific or placebo effect? J Allergy Clin Immunol 128 2011 430 author reply 430-2
34. P.S. Creticos, J.T. Schroeder, R.G. Hamilton, S.L. Balcer-Whaley, A.P. Khattignavong, and R. Lindblad Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis N Engl J Med 355 2006 1445 1455
35. F.C. Lowell, and W. Franklin A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever N Engl J Med 273 1965 675 679
36. S.R. Durham, S.M. Walker, E.M. Varga, M.R. Jacobson, F. O'Brien, and W. Noble Long-term clinical efficacy of grass-pollen immunotherapy N Engl J Med 341 1999 468 475
37. P.S. Creticos, C.E. Reed, P.S. Norman, J. Khoury, N.F. Adkinson Jr., and C.R. Buncher Ragweed immunotherapy in adult asthma N Engl J Med 334 1996 501 506
38. P.S. Creticos Legends in allergy: Philip S. Norman and Lawrence M. Lichtenstein-the Hopkins experience J Allergy Clin Immunol 119 2007 1031 1038
39. L. Cox, H. Nelson, R. Lockey, C. Calabria, T. Chacko, and I. Finegold Allergen immunotherapy: a practice parameter third update J Allergy Clin Immunol 127 1 Suppl 2011 S1 S55